VPRIV (velaglucerase alfa for injection)
FDA INDICATION: Type 1 Gaucher disease. Package Insert
ROUTE OF ADMINISTRATION: Intravenous
DOSAGE AND ADMINISTRATION:
Patients naive to enzyme replacement therapy: 60 Units/kg every other week.
Patients being treated with stable imiglucerase dosages for Gaucher disease can switch to VPRIV at previous imiglucerase dose two weeks after their last imiglucerase dose.
HOW SUPPLIED: 400 units, single-use vials.
DILUENT: 0.9% sodium chloride injection
MAX INFUSION RATE: Physicians can make dosage adjustments based on achievement and maintenance of each patient’s therapeutic goals.
STORAGE REQUIREMENTS: Refrigerate vials at 2–8°C (36–46°F). Do not freeze. Protect from light.
OTHER WEBSITES: vpriv.com, OnePath.com